StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 12, 2026, 04:17 PM

Acrivon Q2 2026 Net Loss $18.0M; Cash $90.0M Funds into Q4 2027

AI Summary

Acrivon Therapeutics reported a net loss of $18.0 million for the second quarter of 2026, an improvement from $21.0 million in the same period of 2025. The company's cash, cash equivalents, and marketable securities stood at $90.0 million as of June 30, 2026, which is expected to fund operations into the fourth quarter of 2027. Key business updates include the upcoming prespecified interim analysis for ACR-368 Phase 2b in the second half of 2026 and the advancement of ACR-2316 into randomized dose expansion.

Key Highlights

  • Net loss for Q2 2026 was $18.0 million, an improvement from $21.0 million in Q2 2025.
  • Research and development expenses decreased to $13.8 million in Q2 2026 from $16.2 million in Q2 2025.
  • General and administrative expenses were $4.8 million in Q2 2026, down from $6.5 million in Q2 2025.
  • Cash, cash equivalents, and marketable securities totaled $90.0 million as of June 30, 2026.
  • Existing cash is expected to fund operations into the fourth quarter of 2027.
  • ACR-368 Phase 2b prespecified interim analysis and data update expected in H2 2026.
  • ACR-2316 Phase 1/2 trial advanced into randomized dose expansion phase.
  • IND filing for CDK11 inhibitor development candidate anticipated in H1 2027.